Oncotelic Therapeutics JV Presents Data Showing Deciparticle Platform Enables Formulation of Diverse Hydrophobic Drugs

Oncotelic Therapeutics Inc. (OTCQB: OTLC) announced that its 45%-owned joint venture, Sapu Nano, presented new data at the 2025 San Antonio Breast Cancer Symposium showing its Deciparticle(TM) nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics into sub-20 nanometer nanoparticles suitable for intravenous delivery. The platform successfully formulated macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams and polyketides, demonstrating broad applicability across different drug classes. According to the company, these findings confirm Deciparticle as a versatile, cGMP-ready delivery platform backed by ISO-5 manufacturing capabilities that support rapid translation to Phase 1 clinical trial supply.

Chief Executive Officer Dr. Vuong Trieu stated the results position Deciparticle as a modular engine for multiple oncology, immunology and peptide drug candidates, with Sapu003 representing the first of a broader pipeline. The ability to consistently formulate hydrophobic drugs into nanoparticles addresses a significant challenge in drug development, as many promising therapeutic compounds have poor solubility that limits their clinical utility. The sub-20 nm particle size is particularly important for intravenous delivery, as smaller nanoparticles typically exhibit better tissue penetration and distribution profiles compared to larger particles.

The ISO-5 manufacturing capabilities referenced in the announcement refer to cleanroom standards that ensure product quality and consistency, which are essential for regulatory approval and clinical translation. The company emphasized that the platform is cGMP-ready, meaning it meets current Good Manufacturing Practice standards required for producing pharmaceuticals for human use. This readiness potentially accelerates the timeline from preclinical development to clinical trials, as the manufacturing process would already comply with regulatory requirements.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, with a mission to address high-unmet-need cancers and rare pediatric indications. The company's joint venture structure with Sapu Nano allows it to benefit from platform technologies while maintaining focus on its core therapeutic areas. The latest news and updates relating to OTLC are available in the company's newsroom at https://nnw.fm/OTLC. The full press release containing additional details about the Deciparticle platform and its applications can be accessed at https://nnw.fm/b0Qps.

The presentation of this data at a major scientific symposium like the San Antonio Breast Cancer Symposium provides external validation of the technology and increases its visibility within the scientific and medical communities. As hydrophobic drugs represent a substantial portion of the pharmaceutical pipeline, platforms that can effectively deliver these compounds could have broad implications across multiple therapeutic areas beyond oncology. The modular nature of the Deciparticle platform suggests it could be applied to various drug candidates, potentially creating multiple development opportunities from a single technological foundation.